Healthcare provider profile · identity verified

Sandhya Narukonda

Internal Medicine · BIRMINGHAM, AL · NPI 1265838445

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	527	192
Amlodipine Besylate	Amlodipine Besylate	471	172
Albuterol Sulfate Hfa	Albuterol Sulfate	302	101
Gabapentin	Gabapentin	265	85
Losartan Potassium	Losartan Potassium	257	92
Pantoprazole Sodium	Pantoprazole Sodium	231	114
Hydrochlorothiazide	Hydrochlorothiazide	227	92
Lisinopril	Lisinopril	201	67
Duloxetine Hcl	Duloxetine Hcl	176	78
Omeprazole	Omeprazole	161	59
Metoprolol Succinate	Metoprolol Succinate	141	55
Carvedilol	Carvedilol	138	55
Rosuvastatin Calcium	Rosuvastatin Calcium	133	49
Trazodone Hcl	Trazodone Hcl	130	30
Diclofenac Sodium	Diclofenac Sodium	126	85
Hydralazine Hcl	Hydralazine Hcl	123	44
Alendronate Sodium	Alendronate Sodium	122	37
Metformin Hcl	Metformin Hcl	117	48
Levothyroxine Sodium	Levothyroxine Sodium	116	34
Furosemide	Furosemide	115	59
Fluticasone Propionate	Fluticasone Propionate	109	50
Eliquis	Apixaban	103	32
Montelukast Sodium	Montelukast Sodium	81	39
Methylprednisolone	Methylprednisolone	80	69
Ozempic	Semaglutide	80	16
Pioglitazone Hcl	Pioglitazone Hcl	78	27
Spironolactone	Spironolactone	78	33
Tizanidine Hcl	Tizanidine Hcl	74	29
Buspirone Hcl	Buspirone Hcl	72	26
Clopidogrel	Clopidogrel Bisulfate	68	20
Prednisone	Prednisone	68	34
Famotidine	Famotidine	65	31
Sertraline Hcl	Sertraline Hcl	60	24
Allopurinol	Allopurinol	58	20
Metformin Hcl Er	Metformin Hcl	58	28
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	57	42
Potassium Chloride	Potassium Chloride	56	21
Glipizide	Glipizide	55	20
Ibuprofen	Ibuprofen	54	34
Metoprolol Tartrate	Metoprolol Tartrate	49	27
Meclizine Hcl	Meclizine Hcl	48	22
Tamsulosin Hcl	Tamsulosin Hcl	47	25
Mirtazapine	Mirtazapine	46	27
Fluconazole	Fluconazole	45	21
Ondansetron Odt	Ondansetron	45	29
Triamcinolone Acetonide	Triamcinolone Acetonide	44	30
Jardiance	Empagliflozin	42	18
Doxycycline Monohydrate	Doxycycline Monohydrate	41	31
Nifedipine Er	Nifedipine	40	13
Pravastatin Sodium	Pravastatin Sodium	40	16
Azithromycin	Azithromycin	39	36
Sildenafil Citrate	Sildenafil Citrate	39	13
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	38	21
Levetiracetam	Levetiracetam	37	suppressed
Pregabalin	Pregabalin	36	11
Januvia	Sitagliptin Phosphate	35	suppressed
Ezetimibe	Ezetimibe	33	suppressed
Torsemide	Torsemide	32	suppressed
Ipratropium Bromide	Ipratropium Bromide	31	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	31	suppressed
Donepezil Hcl	Donepezil Hcl	30	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	12
Ventolin Hfa	Albuterol Sulfate	30	suppressed
Xarelto	Rivaroxaban	30	suppressed
Latanoprost	Latanoprost	29	suppressed
Simvastatin	Simvastatin	29	suppressed
Tresiba Flextouch U-100	Insulin Degludec	29	suppressed
Tramadol Hcl	Tramadol Hcl	27	12
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	24	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	20
Citalopram Hbr	Citalopram Hydrobromide	23	12
Clonazepam	Clonazepam	23	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	18
Symbicort	Budesonide/Formoterol Fumarate	23	suppressed
Lactulose	Lactulose	22	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	19
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	11
Amoxicillin	Amoxicillin	17	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	16
Enalapril Maleate	Enalapril Maleate	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Baclofen	Baclofen	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Metronidazole	Metronidazole	14	13
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Myrbetriq	Mirabegron	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Atenolol	Atenolol	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Modafinil	Modafinil	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error